Zoe Weinstein

Learning Collaboratives in the HEALing Communities Study: An Approach to Providing Training and Technical Assistance

Maria Rudorf, Trevor Baker, Curtis Walker, Nicholas Bove et autres

BACKGROUND: Reducing opioid overdose death rates across the United States demands novel community partnerships and information sharing to implement and sustain evidence-based opioid overdose prevention strategies. During the NIH-funded HEALing Communities Study, a multisite intervention to reduce opioid overdose deaths, researchers from …

us (code pays fourni par la source)

Implementation of addiction consult services and bridge clinics in the HEALing communities study in Massachusetts

Zoe Weinstein, Elizabeth Jadovich, Mari‐Lynn Drainoni, Marc R. Larochelle et autres

us (code pays fourni par la source)

Impacts of personal or family COVID-19 infection on health-related quality of life among patients with opioid use disorder

Zoe Weinstein, Kara M. Magane, Sara Lodi, Margaret Shea et autres

Objective: To assess the impacts of personal or family COVID-19 infection on health-related quality of life (HRQOL) among patients with opioid use disorder (OUD). Methods: From July 2021-July 2022, adults recruited from an OUD treatment clinic self-reported personal or family experiences of …

us (code pays fourni par la source)

Perspectives on Clinical Champions Implementing Hospital-Based Opioid Treatment in US Hospitals

Linda Peng, Amelia Goff, Alisa Patten, Angela R Bazzi et autres

Importance: Hospital-based opioid treatment (HBOT) can improve outcomes for patients with opioid use disorder, but little is known about specific attributes and supports needed for clinical champions to successfully implement HBOT. Objective: To identify characteristics and supports of effective clinical champions implementing …

us (code pays fourni par la source)

Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose

Miriam Harris, Zoe Weinstein, Alexander Y. Walley

Importance: Opioid use disorder (OUD) involves compulsive opioid use that causes substantial distress or impairment at work, school, or home. OUD, which is the third most prevalent substance use disorder worldwide, affected an estimated 3.7% of US adults (9 367 000) in …

us (code pays fourni par la source)

Differences in benefits of office based opioid treatment: Secondary analyses across sub‐groups in the PROUD randomized controlled implementation trial

Katharine A. Bradley, Noorie Hyun, Abisola Idu, Onchee Yu et autres

BACKGROUND AND AIMS: Female, Hispanic, and Black patients with opioid use disorder (OUD) are less likely to receive OUD medication treatment than other patients. The PROUD (PRimary care Opioid Use Disorders treatment) trial demonstrated that implementation of primary care (PC) nurse care …

us (code pays fourni par la source)

Actions Needed for Pharmacy-Dispensed Methadone for Opioid Use Disorder in the United States

Zoe Weinstein, Jeffrey Bratberg, Paul J. Joudrey, David A. Fiellin

us (code pays fourni par la source)

Associations between COVID impact domains and time to buprenorphine treatment disengagement

Zoe Weinstein, Kara M. Magane, Sara Lodi, Delilah Doeleman et autres

Background: People with opioid use disorder (OUD) experienced worse outcomes from the COVID-19 pandemic, which disrupted general medical care.Objectives: To quantify COVID-19 impact on OUD treatment disengagement among patients in office-based addiction treatment (OBAT) with buprenorphine.Methods: We recruited 112 outpatients actively on …

us, vn (code pays fourni par la source)

Patient and Provider Perspectives on the Elimination of Urine Drug Testing in Office-Based Addiction Treatment

J. Theisen, Zoe Weinstein, Melissa Davoust, Alicia S. Ventura et autres

BACKGROUND: Within office-based addiction treatment (OBAT) for opioid use disorder, routine urine drug testing (UDT) has been a near-universal practice, despite concerns about increased stigma and limited evidence on improved patient outcomes. During the COVID-19 pandemic, routine UDT was suspended in many …

us (code pays fourni par la source)

Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study

Melissa Davoust, Angela R. Bazzi, Samantha Blakemore, Juliana Blodgett et autres

BACKGROUND: Deaths from opioid overdose have increased dramatically in the past decade. For individuals with opioid use disorder (OUD), agonist medications such as methadone and buprenorphine reduce opioid-related morbidity and mortality. Historically, the provision of buprenorphine treatment in office-based settings has relied …

us (code pays fourni par la source)

HIV Pre- and Post-Exposure Prophylaxis Prescribing for Hospitalized People who Inject Drugs Cared for by an Addiction Consult Service

Paul J. Christine, Hallie Rozansky, Morgan Younkin, Jason M. Fox et autres

us (code pays fourni par la source)

Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder

Gavin Bart, Kelly S. Barth, Paulette Baukol, Eva A. Enns et autres

BACKGROUND: Hospitalizations involving opioid use disorder (OUD) are increasing. Addiction consultation services (ACS) initiate medications for opioid use disorder (MOUD) in hospital settings and arrange post-hospital follow-up for ongoing MOUD care. Engagement in MOUD following hospital discharge is hampered by challenges in …

us (code pays fourni par la source)